A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone (Q35177672)

6 August 2017

1 reference

title

A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone (English)

1 reference

6 August 2017

Donald S Robinson

1 reference

6 August 2017

J M Ad Sitsen

series ordinal

1 reference

6 August 2017

Michael Gibertini

series ordinal

1 reference

6 August 2017

language of work or name

1 reference

1 June 2003

1 reference

6 August 2017

published in

Clinical Therapeutics

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

1618-1633

1 reference

Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

Is there a role for 5-HT1A agonists in the treatment of depression?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

Blockade of alpha 2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

Effect of food on the bioavailability of gepirone in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

The site of gastrointestinal absorption of gepirone in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

Gepirone in the treatment of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

A Placebo-Controlled Study of Fluoxetine Versus Imipramine in the Acute Treatment of Atypical Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980159-5

7 January 2021

10.1016/S0149-2918(03)80159-5

Identifiers

DOI

1 reference

6 August 2017

1 reference